Safety Study of SEA-CD40 in Cancer Patients

Conditions:   Cancer;   Carcinoma;   Carcinoma, Non-Small-Cell Lung;   Carcinoma, Squamous Cell;   Hematologic Malignancies;   Hodgkin Disease;   Lymphoma;   Lymphoma, B-Cell;   Lymphoma, Follicular;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin;   Melanoma;   Neoplasms;   Neoplasm Metastasis;   Neoplasms, Head and Neck;   Neoplasms, Squamous Cell;   Non-Small Cell Lung Cancer;   Non-Small Cell Lung Cancer Metastatic;   Non-small Cell Carcinoma;   Squamous Cell Cancer;   Squamous Cell Carcinoma;   Squamous Cell Carcinoma of the Head and Neck;   Squamous Cell Neoplasm
Interventions:   Drug: SEA-CD40 monotherapy regimen;   Drug: Pembrolizumab;   Drug: SEA-CD40 combination therapy regimen
Sponsor:   Seattle Genetics, Inc.
Recruiting - verified May 2017

http://ift.tt/2rjoLJF